Mouse Anti-Human CD213a2 Monoclonal Antibody, Clone B-D13, Azide free

Contact us
Diaclone
Product Code: 852.120.005
Product Group: Primary Antibodies
Supplier: Diaclone
CodeSizePrice
852.120.005500ug/500ul£419.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Mouse
Antibody Isotype: IgG1
Antibody Clonality: Monoclonal
Antibody Clone: B-D13
Regulatory Status: RUO
Target Species: Human

Further Information

Antigen:
CD213a2 / IL-13Ra2
Antigen Synonyms:
IL-13Ra2
Conjugate:
Azide free
Format:
Phosphate-buffered saline. Sterile-filtered through 0.22 µm. Carrier and preservative free
Hybridoma:
Myeloma X63/AG.8653 x Balb/c spleen cells
Immunisation:
IL-13Ra2 transfected CHO cell line
Reactivity:
Human
Research Area:
Cytokine / Chemokine ReceptorsCD Markers
Specificity:
Recognises the IL-13 receptor a2 (IL-13 Ra2) a 44 kDa protein
Workshop:
VII

References

  1. Blanchard C. et al. J. Immunol. 2004; 172(6): 3775 - 3783. IL-4 and IL-13 Up-Regulate Intestinal Trefoil Factor Expression: Requirement for STAT6 and De Novo Protein Synthesis. https://www.ncbi.nlm.nih.gov/pubmed/15004182
  2. Jain M. et al. Cancer2012; 118(22): 5698-708.. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma. https://www.ncbi.nlm.nih.gov/pubmed/22570059
  3. Joshi B. H. et al. Clin. Cancer Res. 2002; 8(6) : 1948 - 1956. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. https://www.ncbi.nlm.nih.gov/pubmed/12060640
  4. Joshi B. H. et al. Cancer Res.2000; 60(5): 1168-72.. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. https://www.ncbi.nlm.nih.gov/pubmed/10728667
  5. Kawakami K. et al. Clin. Cancer Res. 2003; 9(17): 6381 - 6388. Interleukin-13 receptor alpha2 chain in human head and neck cancer serves as a unique diagnostic marker. https://www.ncbi.nlm.nih.gov/pubmed/14695138
  6. Kawakami K. et al. J. Immunol. 2002; 169(12): 7119 - 7126. IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer. https://www.ncbi.nlm.nih.gov/pubmed/12471149
  7. Kawakami K. et al. Mol. Cancer Ther. 2004; 3(2) : 137 - 147. Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease. https://www.ncbi.nlm.nih.gov/pubmed/14985454
  8. Kawakami K. et al. Clin Cancer Res.2006; 12(15): 4678-86.. Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors. https://www.ncbi.nlm.nih.gov/pubmed/16899618
  9. Lordan J L. et al. J. Immunol. 2002; 169(1) : 407 - 414. Cooperative effects of Th2 cytokines and allergen on normal and asthmatic bronchial epithelial cells. https://www.ncbi.nlm.nih.gov/pubmed/12077271
  10. MadhankumarA.B. et al.PLoS One 2018 Jan 5;13(1):e0181529. Tumor targeted delivery of doxorubicin in malignant peripheral nerve sheath tumors.. https://www.ncbi.nlm.nih.gov/pubmed/29304038
  11. Moynihan B. J. et al.Respir Res.2008; 9: 84.. IFN-gamma IL-4 and IL-13 modulate responsiveness of human airway smooth muscle cells to IL-13.. https://www.ncbi.nlm.nih.gov/pubmed/19116009
  12. Ou W. et al.Hum Gene Ther Methods2012; 23(2): 137-47. Specific targeting of human interleukin (IL)-13 receptor alpha2-positive cells with lentiviral vectors displaying IL-13.. https://www.ncbi.nlm.nih.gov/pubmed/22612657